Focus: Vir Biotechnology is a San Francisco-based biotech company focused on infectious disease therapies, with a diverse pipeline spanning COVID-19, influenza, hepatitis B/D, and HIV. The company operates as a mid-cap biotech with active clinical programs across multiple therapeutic areas.
Profile data last refreshed 22m ago · AI intelligence enriched 2w ago
Stable — net -4 jobs in 30d
6 added, 10 removed. Backfill posture.
Best fit for supply chain, CMC, and clinical development professionals seeking exposure to viral disease programs with near-term catalysts; less attractive for researchers or those requiring visa sponsorship.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Vir Biotechnology
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vir Biotechnology's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Vir Biotechnology Appoints Aziz Sawaf as EVP and CFO - Contract Pharma
Vir Biotechnology Appoints Aziz Sawaf as EVP and CFO Contract Pharma
Vir Biotechnology gains from pharma deals and h... - Pluang
Vir Biotechnology gains from pharma deals and h... Pluang
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - businesswire.com
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference businesswire.com
Vir Biotechnology Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Vir Biotechnology Number of Employees 2026 | Employee Count & Headcount Data Revelio Labs
8-K Filing: Olema Pharmaceuticals, Inc. (OLMA) (CIK 0001750284) — EX-99.1
EX-99.1
Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer - Contract Pharma
Vir Biotechnology Appoints Brent Sabatini as Interim Principal Financial Officer Contract Pharma
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo